title: Impaired and imbalanced cellular immunological status assessed in advanced cancer patients and restoration of the T cell immune status by adoptive T-cell immunotherapy.
abstract: Recent progress has been made in understanding the mechanisms of antitumor immune responses, which may further clarify the immune status of cancer patients. In this study, we performed a detailed evaluation of the immunological status of 47 patients with advanced solid cancer, who had received no immunosuppressive treatment, and compared the results with 32 healthy subjects. Flow-cytometry data for peripheral blood were obtained using 19 monoclonal antibodies against various cell surface and intracellular molecules. Absolute numbers of T cells, several T cell subsets, B cells, and NK cells were significantly decreased in patients compared with healthy subjects. The percentage of CD27(+)CD45RA(+) T cells was lower and that of CD27(-)CD45RA(-) T cells was higher in patients compared with controls. Regulatory and type 2 helper T cells were elevated in patients relative to healthy subjects. The percentage of perforin(+) NK cells was significantly lower in patients than in controls. These results suggest a dysfunctional anti-tumor immune response in cancer patients. Furthermore, peripheral blood from 26 of 47 cancer patients was analyzed after adoptive T cell immunotherapy (ATI). ATI increased the number of T cell subsets, but not B and NK cells. The number and percentage of regulatory T cells decreased significantly. These results suggest that ATI can restore impaired and imbalanced T cell immune status.
authors.affiliation: Seta Clinic Group, 3-6-5 Iidabashi, Chiyoda-ku, Tokyo 102-0072, Japan; Medinet Co., Ltd., Shin-Yokohama Square Bldg. 14F, 2-3-12 Shin-Yokohama, Kohoku-ku, Yokohama 222-0033, Japan.
authors.forename: Atsutaka
authors.initials: A
authors.lastname: Noguchi
authors.affiliation: Seta Clinic Group, 3-6-5 Iidabashi, Chiyoda-ku, Tokyo 102-0072, Japan.
authors.forename: Toru
authors.initials: T
authors.lastname: Kaneko
authors.affiliation: Seta Clinic Group, 3-6-5 Iidabashi, Chiyoda-ku, Tokyo 102-0072, Japan.
authors.forename: Keiko
authors.initials: K
authors.lastname: Naitoh
authors.affiliation: Seta Clinic Group, 3-6-5 Iidabashi, Chiyoda-ku, Tokyo 102-0072, Japan.
authors.forename: Masashi
authors.initials: M
authors.lastname: Saito
authors.affiliation: Seta Clinic Group, 3-6-5 Iidabashi, Chiyoda-ku, Tokyo 102-0072, Japan.
authors.forename: Kazuro
authors.initials: K
authors.lastname: Iwai
authors.affiliation: Medinet Co., Ltd., Shin-Yokohama Square Bldg. 14F, 2-3-12 Shin-Yokohama, Kohoku-ku, Yokohama 222-0033, Japan.
authors.forename: Ryuji
authors.initials: R
authors.lastname: Maekawa
authors.affiliation: Seta Clinic Group, 3-6-5 Iidabashi, Chiyoda-ku, Tokyo 102-0072, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Kamigaki
authors.affiliation: Seta Clinic Group, 3-6-5 Iidabashi, Chiyoda-ku, Tokyo 102-0072, Japan. Electronic address: goto@j-immunother.com.
authors.forename: Shigenori
authors.initials: S
authors.lastname: Goto
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001402:B-Lymphocytes / Q000276:immunology*; D002452:Cell Count; D002478:Cells, Cultured; D016207:Cytokines / Q000378:metabolism; D005260:Female; D006304:Health Status; D006706:Homeostasis; D006801:Humans; D007111:Immunity, Cellular; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007694:Killer Cells, Natural / Q000276:immunology*; D016131:Lymphocyte Subsets / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009369:Neoplasms / Q000175:diagnosis / Q000276:immunology*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*; D016896:Treatment Outcome
chemical_list: D016207:Cytokines
keywords: Adoptive immunotherapy; Flow cytometry; Immunological status; T cell